Medical news today: Tuesday, November 3, 2026
A US bird flu death, India's batch checks on cough-syrup solvents, and an FDA choking warning on toddler bars
Get tomorrow's issue in your inbox.
- 01
FDA approves generic lenacapavir, the twice-a-year HIV prevention shot
Source: MedPage Today
MedPage Today reports: (MedPage Today) -- The FDA has approved a generic version of lenacapavir (Yeztugo), the world's only twice-a-year shot to prevent HIV -- a big step toward making the drug available inexpensively and more quickly in 120 low- and middle-income...
Why it mattersA generic version of lenacapavir (Yeztugo) is a big step toward making the only twice-a-year HIV prevention shot available cheaply and faster in 120 low- and middle-income countries. More on Approvals & regulatory →
- 02
Centre proposes mandatory qualified personnel for drug batch release
Source: Business Standard
Why it mattersIndia’s government wants a qualified person to be required before drug batches are released, a change that would affect how manufacturers sign off on product quality.
- 03
Lonza buys Merck KGaA’s CDMO business in a bet on US growth
Source: Fierce Pharma
Why it mattersThe deal expands Lonza’s contract development and manufacturing business as it pushes for growth in the US market. More on Pharma industry →
- 04
Drugmakers seek clarity on whether CDSCO solvent rule covers exports
Source: Business Standard
Business Standard reports: The CDSCO order requiring a system-generated NOC before every batch of high-risk pharma solvents is distributed does not separate domestic and export quantities, and executives want a clarification. They also warn that short-staffed state drug departments could delay clearances, hitting smaller manufacturers and rural supplies first.
Why it mattersThe rule follows the 2025 Coldrif cough syrup deaths of 24 children in Madhya Pradesh, so how it is applied will shape both supply chain traceability and whether syrups keep reaching small-town pharmacies on time. More on Drug & device safety →
- 05
Studies raise doubts over three-parent IVF meant to prevent mitochondrial disease
Source: STAT
STAT reports that scientists and ethicists are rethinking the potential risks and benefits of mitochondrial replacement, a technology meant to stop babies inheriting rare mitochondrial diseases.
Why it mattersThe technique was meant to prevent rare inherited mitochondrial diseases, so new doubts from studies could shape how clinics and regulators weigh its risks and benefits. More on Approvals & regulatory →
- 06
Bayer raises 2026 profit outlook as pharma sales beat forecasts
Source: Reuters
Reuters reports Bayer now expects 2026 adjusted core earnings of €9.8-10.3 billion, up from €9.6-10.1 billion, after its pharmaceuticals unit posted third-quarter sales of €4.68 billion, 5% above analyst expectations. It also cut its year-end net debt forecast by €1 billion to €28-29 billion.
Why it mattersCEO Bill Anderson says Bayer pharma has reached a turning point, with growth led by Nubeqa and Kerendia offsetting falling Xarelto and Eylea sales after patent expiries. More on Pharma industry →
Market news · Not investment advice
- 07
Sun Pharma shares slip 3% after one-off charges cut quarterly profit 36%
Source: Moneycontrol
India's Sun Pharmaceutical Industries shares fell over 3% on 2 November after consolidated net profit dropped 36.36% to Rs 1,988.53 crore for the September quarter, hit by one-time costs tied to its proposed Organon acquisition and US litigation, Moneycontrol reports. India formulation sales rose 17.3%, and most brokerages kept positive ratings while trimming target prices.
Why it mattersSun Pharma is India's largest drugmaker and a big exporter of generics, so its results matter for Indian investors, pharma jobs and the supply of affordable medicines. Not investment advice. More on Pharma industry →
Market news · Not investment advice
- 08
SGLT2 diabetes-kidney pills help adults over 80 with kidney disease, study finds
Source: Medical Xpress
SGLT2 inhibitors (a class of tablets first used for diabetes, such as empagliflozin and dapagliflozin) showed significant benefits for adults aged 80 and older with chronic kidney disease, according to a study presented at the American Society of Nephrology's Kidney Week in Denver (21-25 October).
Why it mattersVery old patients are often left out of trials, so evidence that these widely used, increasingly generic pills help them too could shape how families and doctors weigh treatment for elderly relatives with weak kidneys. More on Obesity & metabolic →
- 09
FDA grants speedy approval to Voceryq for wart-like airway disease
Source: MedPage Today
The US FDA granted accelerated approval to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid) to reduce how often adults with recurrent respiratory papillomatosis need surgery to remove growths, MedPage Today reports.
Why it mattersRecurrent respiratory papillomatosis is a rare HPV-linked condition in which wart-like growths keep returning in the airway, so patients can face repeated operations; a drug that cuts those surgeries could ease that burden. "Accelerated approval" means the FDA can still ask for confirmatory evidence. More on Approvals & regulatory →
- 10
Drug-coated balloons match stents for new artery blockages in TRANSFORM II trial
Source: MedPage Today
In the TRANSFORM II trial, presented at the TCT heart meeting, drug-coated balloons were just as effective as standard drug-eluting stents for first-time (de novo) narrowings in heart arteries treated with angioplasty (PCI), MedPage Today reports.
Why it mattersIf balloon-only treatment holds up, some heart patients could have blocked arteries opened without leaving a permanent metal stent behind, which may change procedure choices and costs.
- 11
Mitapivat lifts hemoglobin in sickle cell but misses on pain crises
Source: MedPage Today
MedPage Today reports: (MedPage Today) -- The thalassemia drug mitapivat (Aqvesme) significantly improved hemoglobin response in patients with sickle cell disease but failed to top placebo when it came to reducing pain crises in a phase III trial that aims to support...
Why it mattersIn a phase III trial, the thalassemia drug mitapivat (Aqvesme) improved hemoglobin response but did not beat placebo at reducing pain crises, a mixed result for its use in sickle cell disease.
- 12
Washington state resident dies of bird flu after dairy-cattle exposure
Source: STAT (Associated Press)
A Yakima County, Washington resident with previous health conditions died Sunday of H5N1 bird flu complications after exposure at a dairy with infected cattle, the first such US death in a year, AP reports. County officials say 33 dairy herds have recently tested positive for H5N1.
Why it mattersIt is the third US death tied to bird flu since 2024 and a reminder that the virus is still spreading among animals worldwide; farm workers and people handling sick animals face the highest exposure. More on Drug & device safety →
- 13
Karyopharm files for bankruptcy and lines up Gamida Cell parent as lead bidder
Source: BioPharma Dive
Cancer drugmaker Karyopharm will sell itself in a court-supervised bankruptcy auction, with Ayrmid, the parent of cell therapy maker Gamida Cell, as lead bidder, BioPharma Dive reports. The company had recently cut a forbearance deal to push off debt payments.
Why it mattersWhen a small drugmaker goes bankrupt, shareholders can be wiped out, and patients and doctors watch whether its marketed medicines stay available under a new owner. Not investment advice. More on Oncology →
- 14
Estée Lauder raises full-year outlook as fragrance sales climb 20%
Source: Cosmetics Business
The Estée Lauder Companies (owner of MAC, Clinique, Jo Malone London and Tom Ford Beauty) said net sales rose 7% to US$3.7bn in fiscal Q1 2027 and raised its full-year organic sales growth forecast to 4%-5.5%, with fragrance organic sales up 20%.
Why it mattersA strong quarter at one of the world's biggest beauty groups shows shoppers are still spending on prestige perfume and skincare, which shapes prices, promotions and jobs across the cosmetics industry. More on Pharma industry →
- 15
US supplier Maypro takes exclusive rights to shatavari extract for women's health
Source: NutraIngredients
Maypro Industries has secured exclusive US distribution rights for Aspurūs, a shatavari root extract (an Ayurvedic herb) developed by Waleria Healthtech for women's health. The companies say clinical studies showed reduced menopause-related symptoms such as fatigue and hot flashes (company-reported).
Why it mattersHerbal menopause supplements are a fast-growing market; the benefits here are as reported by the companies, and supplements are not reviewed for effectiveness the way medicines are, so shoppers should treat label claims with care. More on Approvals & regulatory →
- 16
India's drug regulator requires digital clearance for every batch of cough-syrup solvents
Source: Business Standard
India's Central Drugs Standard Control Organisation (CDSCO) has ordered that no batch of 10 high-risk pharmaceutical solvents, including propylene glycol, glycerine, maltitol and sorbitol, be distributed until it is registered on a government digital system and gets an automatic no-objection certificate, Business Standard reports. Industry executives warned of possible short-term clearance delays.
Why it mattersThese ingredients go into cough syrups and other liquid medicines, and contaminated batches have been linked to child deaths, so tracking every batch aims to keep toxic syrups off shelves in India and in the countries it exports to. More on Approvals & regulatory →
- 17
Keytruda biosimilars near, but analysts see an uphill fight for market share
Source: BioPharma Dive
A patent cliff is fast approaching for Merck's blockbuster cancer immunotherapy Keytruda, but its biosimilars (near-identical, usually cheaper copies of biologic drugs) may struggle to win widespread use, BioPharma Dive reports in an analysis.
Why it mattersKeytruda is one of the world's top-selling medicines, so how quickly cheaper copies catch on will affect what patients, insurers and health systems pay for cancer care. More on Oncology →
Market news · Not investment advice
- 18
FDA warns not to buy or serve Once Upon a Farm toddler bars over choking risk
Source: FDA
The FDA says it has received several reports of toddlers aged 1.5-2.5 years suffering complete airway blockage after eating Once Upon a Farm Tractor Wheels organic soft-baked bars, which reportedly form a dry, sticky mass that back blows and the Heimlich manoeuvre may fail to clear. The bars are sold nationwide in the US, including at Costco, Target, Walmart and online.
Why it mattersThe FDA tells families to stop serving these bars and throw them away, and to call emergency services if a child is choking and first aid fails; parents who bought them online outside the US should check too. More on Approvals & regulatory →
- 19
FDA flags high-risk B. Braun dialysis tubing removal over connector leaks
Source: FDA
The FDA issued an early alert after B. Braun told customers to stop using and quarantine three lots of its Streamline Bloodline Set for the Dialog+ dialysis machine, because a missed assembly step means the connector may leak or detach, risking blood loss or air entering the blood line. B. Braun reported no serious injuries or deaths as of 10 October.
Why it mattersPeople on haemodialysis rely on this tubing several times a week, so clinics need to pull affected lots quickly to avoid interrupted treatments and dangerous blood loss. More on Approvals & regulatory →
More recent digests
- Wednesday, November 18, 2026White House pulls its FDA nominee, the US loses measles elimination status, and FDA offers to share its approval reviews with other regulators
- Tuesday, November 17, 2026US flu deaths in children rise, a Cochrane review backs daily iron for anaemia, and the FDA approves giredestrant for selected breast cancers
- Monday, November 16, 2026Teen tirzepatide trial cuts BMI, US flu season starts early, and the FDA rejects Summit's lung cancer drug
- Sunday, November 15, 2026WHO issues first type 1 diabetes guidance for adults and children; JAMA reports a possible CTE blood biomarker; MP flags mercury creams
- Saturday, November 14, 2026FDA approves a weekly self-injected myasthenia gravis drug; US measles deaths rise; India enforces lower cancer-drug prices
- Friday, November 13, 2026WHO reports persistent TB burden; JAMA publishes new oncology and neonatal sepsis trials; MHRA flags a packaging defect
- Thursday, November 12, 2026WHO reports continuing Ebola emergency and African regulatory advances; FDA approves first FXIa inhibitor for secondary stroke prevention
Free daily email
The day's approvals, safety signals and trials, in five minutes.
Join the list with just your email. You can also follow the RSS feed.
